Wednesday - November 28, 2018

Bayer partners with Ho Chi Minh City Stroke Association to enhance scientific knowledge of cardiovascular diseases in Vietnam

Ho Chi Minh City, November 24, 2018 – Bayer (South East Asia) Pte. Ltd. in Ho Chi Minh City (Bayer SEA) supported the Ho Chi Minh City Stroke Association in their effort to enhance the knowledge and competence of medical doctors in Vietnam, by organizing a satellite meeting as part of a symposium from 24 to 25 November.

Prof. Nguyen Huy Thang, Chairman of Ho Chi Minh City Stroke Association, chaired both the whole symposium as well as the satellite meeting, which was on the main topic of “Optimizing Stroke Prevention for Patients with non-valvular atrial fibrillation (AF) with co-morbidities.”

 

More than 700 doctors, made up of local cardiologists, neurologists, ICU and geriatrics, as well as local and international experts, gathered to exchange the latest knowledge and share best practices on stroke management. The symposia also provided the most up-to-date insights on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in addressing patient’s unmet medical needs in thrombosis management.

 

Patients with atrial fibrillation (AF), which is a popular heart rhythm disorder, are at a five-fold risk of stroke in comparison to that of patients without AF. AF-related strokes are more likely to cause patients to remain in hospitals longer, and to face a higher risk of disability and death, than strokes due to other causes.

Prof. Nguyen Huy Thang, Chairman of Ho Chi Minh City Stroke Association shared new insight on stroke prevention.

 

“Oral anticoagulants (NOACs) offer a new standard of care in preventing AF-related strokes, and its use in AF patients has been recommended in current treatment guidelines. NOACs are considered a medical advancement which overcomes the limitations of vitamin K antagonists (VKAs) – with proven advantages such as fixed doses, less medicine and food interaction, no blood test monitoring needed, and offering better convenience for patients. Importantly, in comparison with VKAs, NOACs have been proven to offer equal efficacy and significantly reduce the rate of major bleeding such as intracranial hemorrhage and fatal bleeding," explained Prof. Nguyen Huy Thang.

 

The world’s population is not only fast expanding, but also aging. Accounting for more than half of the world's population, Asia Pacific will add close to 580 million people by 2050. The region is at the same time experiencing aging at an unprecedented rate – the percentage of older persons aged 60 years and above is set to double from 12 percent to 24 percent by 2050[1], and age-related medical conditions like cancer, cardiovascular diseases and diabetes are on the rise.


Cardiovascular diseases, in particular, will remain a key area of medical need in the region. Mirroring the burden imposed globally, cardiovascular diseases have been a leading cause of death, accounting for 8.2 million cases of mortality in 2015. This is an increase of 21% from 6.8 million in 2005[2].


In Vietnam, according to Prof. Nguyen Huy Thang, there are more than 200,000 stroke patients each year. About 40% of patients with AF-related strokes die; and 70% of stroke survivors suffer from stroke sequels.

 

Although the frequency is higher in elderly patients, this disease also affects a sizeable segment of the younger population. Alarmingly, many people will only find out they have AF when they actually have a stroke, which can lead to greater disability and worse patient outcomes.

 

The good news is that Bayer’s NOACs have demonstrated real-world[3] stroke prevention outcomes and safety in NVAF patients across different risk profiles, with proven low major bleeding rates across Asian patients, high risk patients with co-morbidities[4] and patients with kidney impairment[5].Moving forward, it is important for increased awareness in the region about how NOACs can best support doctors in the region, in their management and prevention of AF-related strokes.

Prof. Andrew Lee, Director, Centre for Neuroscience Innovation, Flinders University and the Calvary Wakefield Hospital, Australia, presented topic “Optimizing Stroke Prevention for Patients with non-valvular atrial fibrillation (AF) with co-morbidities.”

 

“As a Life Science company, Bayer is committed to supporting and organizing scientific symposia for medical doctors. Bayer collaborates with institutions worldwide in the field of research and clinical studies, in order to help medical doctors obtain the best and latest therapy for the benefit of their patients. Towards this end, we are privileged to be able to put our full support behind the Ho Chi Minh City Stroke Association in their annual scientific meeting this year. I am certain that this meeting will bring much-needed information to the medical community in Vietnam, especially about the excellent outcomes of NOACs in preventing strokes in AF patients, so that cardiovascular diseases can be managed more effectively. What Ho Chi Minh City Stroke Association is doing is in line with Bayer’s mission, which is to use our science to help people live better lives”, said Dr. Lynette Moey, Country Division Head of Bayer Pharmaceuticals Division in Vietnam.

Panel discussion among experts in stroke prevention for non-valvular atrial fibrillation patients

 

About Bayer


Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.


Forward-Looking Statements


This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.